U.S. markets closed

Vascular Biogenics Ltd. (VBLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.1530+0.0008 (+0.53%)
At close: 04:00PM EST
0.1551 +0.00 (+1.37%)
After hours: 07:36PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close0.1522
Bid0.1530 x 900
Ask0.1577 x 3000
Day's Range0.1530 - 0.1593
52 Week Range0.1080 - 2.2900
Avg. Volume1,434,182
Market Cap10.672M
Beta (5Y Monthly)0.64
PE Ratio (TTM)N/A
EPS (TTM)-0.4690
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VBLT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vascular Biogenics Ltd.
    Daily – Vickers Top Buyers & Sellers for 10/06/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Insider Monkey

    13 Best Biotech Penny Stocks To Buy Now

    In this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go directly to see the 5 Best Biotech Penny Stocks To Buy Now. Biotechnology is a sector that has long been contributing to the improvement of […]

  • Zacks

    Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates

    Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -9.09% and 220.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Continued progress on previously announced strategic process to maximize shareholder valueTEL AVIV, Israel and NEW YORK, Nov. 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced financial results for the third quarter ended September 30, 2022, and provided a corporate update. “VBL’s management team and board continue to make good progress on the evaluation of strategic